Serum 25-hydroxyvitamin D levels associated with disease severity in children with allergic rhinitis and adenoid hypertrophy

This retrospective observational study evaluated 268 children between 3 and 12 years of age diagnosed with both allergic rhinitis and adenoid hypertrophy. The primary exposure was serum 25-hydroxyvitamin D [25(OH)D] levels, with patients stratified specifically against those exhibiting severe deficiency. The analysis focused on the association between these vitamin D levels and overall disease severity.

secondary outcomes included the adenoidal-nasopharyngeal (A/N) ratio, total and specific IgE concentrations, and symptom scores. The study design did not report specific numerical values for the main results or secondary outcomes, nor did it document any adverse events, serious adverse events, discontinuations, or tolerability data. Consequently, no specific efficacy or safety metrics can be extracted from the provided evidence.

Key limitations inherent to this retrospective observational approach prevent establishing causal relationships between vitamin D levels and disease outcomes. The absence of reported numerical data for primary and secondary outcomes restricts the precision of any clinical interpretation. Furthermore, the lack of reported funding sources or conflicts of interest limits the ability to fully assess potential biases.

Given the observational nature of the study and the missing quantitative data, the practice relevance remains uncertain. Clinicians should interpret these findings as preliminary associations rather than definitive evidence for clinical management. Further prospective research with detailed outcome reporting is necessary to determine if vitamin D supplementation impacts disease severity in this pediatric population.